J Med Microbiol 57 (2008), 856-863; DOI: 10.1099/jmm.0.2008/000521-0
© 2008 Society for General Microbiology
ISSN 1473-5644
Molecular characterization of multidrug-resistant Shigella species isolated from epidemic and endemic cases of shigellosis in India
Gururaja Perumal Pazhani1,
Swapan Kumar Niyogi1,
Anil Kumar Singh2,
Bhaswati Sen1,
Neelam Taneja3,
Manikuntala Kundu2,
Shinji Yamasaki4 and
Thandavarayan Ramamurthy1
1 National Institute of Cholera and Enteric Diseases, Kolkata, India
2 Department of Chemistry, Bose Institute, Kolkata, India
3 Department of Microbiology, Post Graduate Institute of Basic Medical Sciences, Chandigarh, India
4 Osaka Prefecture University, Osaka, Japan
Correspondence
Thandavarayan Ramamurthy
tramu{at}vsnl.net
Received 18 January 2008
Accepted 19 March 2008
Shigella species represent one of the growing numbers of antimicrobial-resistant bacteria in developing countries. Fluoroquinolone-resistant strains of Shigella dysenteriae type1 and Shigella flexneri type 2a emerged in India during 2002 and 2003, respectively. Sixty strains of Shigella from different parts of India were analysed for antimicrobial susceptibility, the presence of the qnr plasmid, mutations in the quinolone resistance determining regions (QRDRs), fluoroquinolone accumulation, and the presence of other genes encoding resistance to various antimicrobials. Fluoroquinolone-resistant strains had mutations in gyrA and parC genes and had an active efflux system. They were also resistant to several other antimicrobials but were susceptible to azithromycin and ceftriaxone. The majority of the strains harboured genes encoding resistance to ampicillin (97 %), tetracycline (95 %), streptomycin (95 %) and chloramphenicol (94 %). PFGE analysis revealed clonality among strains of S. dysenteriae types 1 and 5, S. flexneri type 2a and Shigella boydii type 12.
Abbreviations: CCCP, carbonyl cyanide m-chlorophenylhydrazone; QRDR, quinolone resistance determining region.
The GenBank/EMBL/DDBJ accession numbers for the blaCTX-M-3 sequence of S. boydii type 1, the aac(6')-Ib-cr sequence of S. flexneri type 3b, the aac(6')-Ib-cr sequence of S. boydii type 1 and the gyrA and parC sequences for S. boydii type 1 are EF077620, EF501990, EF501993, EF077618 and EF077619, respectively.
 |
INTRODUCTION
|
|---|
Shigellosis remains an important public health problem in developing countries with Shigella sonnei in Europe and the US and Shigella flexneri in Asian and African countries being of epidemiological importance. Antimicrobial therapy is advocated for shigellosis to shorten the duration of illness (Salam & Bennish, 1991). However, in Asia and Africa, antimicrobial resistance is an emerging problem among Shigella species (von Seidlein et al., 2006) and treatment options are becoming limited globally (Salam & Bennish, 1991; Kariuki & Hart, 2001). The World Health Organization has recommended that ciprofloxacin should be considered a first-line antibiotic for the treatment of shigellosis, and the use of nalidixic acid is not encouraged, even in areas where it is still effective against Shigella (WHO, 2004). Similar to the prevalence of different serotypes, antimicrobial-resistance patterns of strains also differ from country to country and even within the same country (Pazhani et al., 2005; von Seidlein et al., 2006), which may be due to the spread of resistant clones as found for multidrug-resistant strains of Shigella dysenteriae type 1 in eastern parts of India (Pazhani et al., 2004). In this study, we have investigated the mechanisms of antibiotic resistance and clonal relatedness of Shigella strains isolated from epidemic and endemic cases of shigellosis in different parts of India.
|
METHODS
|
|---|
Bacterial strains.
We examined 60 strains of Shigella species (20 S. dysenteriae, 16 S. flexneri, 7 Shigella boydii and 17 S. sonnei) isolated from dysentery outbreaks from different parts of India and sporadic hospitalized cases of shigellosis in Kolkata and Goa between 2001 and 2004. Strains were confirmed as Shigella spp. by standard biochemical tests (WHO, 1987) and serotyped using commercially available antisera (Denka Seiken).
Antimicrobial susceptibility testing.
Antimicrobial susceptibility tests were performed by a disc diffusion method in accordance with National Committee of Clinical Laboratory Standards guidelines (NCCLS, 2004) for ampicillin (10 µg), co-trimoxazole (25 µg), tetracycline (30 µg), chloramphenicol (30 µg), streptomycin (10 µg), nalidixic acid (30 µg), ciprofloxacin (5 µg), norfloxacin (10 µg), ofloxacin (5 µg), ceftriaxone (30 µg) and azithromycin (15 µg) (Becton Dickinson). Escherichia coli ATCC 25922 was used for quality control in each batch of tests. MICs of nalidixic acid, ciprofloxacin, norfloxacin, ofloxacin and azithromycin were determined for selected strains by the E-test (AB Biodisk).
Plasmid isolation and Southern hybridization.
Plasmids were isolated from the representative quinolone- and fluoroquinolone-resistant Shigella strains using QIAGEN tip 100. Plasmids were transferred to Hybond-N+ nylon membrane (Amersham Pharmacia) by a capillary method (Sambrook et al., 1989). The membrane was hybridized with a DIG-labelled qnr probe, which was amplified from a qnr-positive strain (J53; pMG252) with published primers (Wang et al., 2003). For hybridization, a DIG-labelling and detection kit was used (Boehringer Mannheim). All strains were also screened with the qnr probe by colony hybridization.
PCR amplification
Amplification of the quinolone resistance determining regions (QRDRs).
QRDRs of gyrA and parC genes were amplified as reported previously (Chu et al., 1998). For each strain, 10 ng of the chromosomal DNA was used in the PCR assay.
Screening of antimicrobial-resistance genes.
PCR was performed to detect genes encoding resistance to ampicillin (blaTEM), gentamicin (aadB), streptomycin (aadA1, strA), kanamycin (aphA1-Ia), chloramphenicol (catA1), tetracycline [tet(A), tet(B), tet(C), tet(D), tet(E) and tet(Y)] and β-lactams (blaOXA-1, blaOXA-7, blaSHV, blaPSE-4 and blaCTX-M-3) and plasmid mediated quinolone resistance (qnr) as published for other organisms (Maidhof et al., 2002; Maynard et al., 2003; Robicsek et al., 2006). The newly designed primers FMEF (5'-GCA ACG CAA AAA CAA AGT TAG G-3') and FMER (5'-GTG TTT GAA CCA TGT ACA-3') were used to detect aac(6')-1b variants. All assays were carried out as single PCR assays except that for the qnr gene, which was performed in a multiplex format, targeting all the three variants of qnrA, qnrB and qnrS. Template DNA was prepared by boiling the cultures grown in Luria–Bertani (LB) broth medium (Difco) for 10 min, rapidly cooled on ice followed by brief centrifugation at 5000 r.p.m.; the supernatant was retained for PCR assays.
Nucleotide sequencing of the PCR products.
PCR products were purified with a QIAquick PCR purification column (Qiagen), and sequencing reactions were carried out using the Big Dye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems). Nucleotide sequencing was performed in both directions with the same PCR primers used for the amplification of the target genes in an automatic sequencer (ABI Prism 3200; Applied Biosystems). Contig sequences were edited with DNASTAR (Lasergene) and compared in BLAST of the NCBI database.
Fluoroquinolone accumulation assay.
Fluoroquinolone-sensitive and -resistant strains of Shigella were grown to mid-exponential phase in LB (OD600 0.4), harvested, and suspended in 0.2 M MOPS/Tris buffer (pH 7.0) to an OD600 of 20 ml–1. Cells were energized with 0.2 % glucose for 20 min and fluoroquinolones were added at a concentration of 10 µg ml–1. Aliquots of this mixture were taken and suspended in 1 ml 100 mM glycine/HCl (pH 3.0), shaken for 1 h at room temperature, and the amount of released fluoroquinolone was determined spectrofluorometrically with excitation at 277 nm and emission at 448 nm. Experiments were performed in triplicate after the addition of carbonyl cyanide m-chlorophenylhydrazone (CCCP) to the assay mixture, as an inhibitor of the proton-motive force, at a final concentration of 100 µM.
PFGE.
DNA fingerprinting was carried out by PFGE with the restriction enzyme XbaI (Takara) according to a standard procedure (CDC, 2000). PFGE run conditions were generated by the autoalgorithm mode of the CHEF Mapper system with a size range of 30–600 kb (Bio-Rad). After gel electrophoresis, gels were stained with ethidium bromide for 30 min and destained for 30 min with distilled water. The gel images were digitalized for computer-aided analysis (Gel Doc 2000; Bio-Rad).
Cluster analysis.
PFGE gel images were retrieved and aligned to generate composite images containing the banding profiles of all the strains. The images were analysed with Diversity Database fingerprinting software (version 2.2.0; Bio-Rad) to determine the relatedness of the strains. Bands ranging from 48.5 to 600 kb were considered for the construction of dendrograms. Degrees of homology were determined by comparison of the Dice coefficient, and clustering correlation coefficients were calculated by an unweighted pair-group method with arithmetic averages (UPGMA). A dendrogram showing the hierarchical representation of the level of linkage between the strains was drawn to predict the degree of clonal relatedness.
|
RESULTS AND DISCUSSION
|
|---|
Antimicrobial resistance
Table 1
shows the breakdown of the serotypes of the 60 Shigella strains, their antimicrobial-resistance profiles and resistance gene complement. S. dysenteriae type 1 strains (n=17) were uniformly resistant to all the tested antimicrobials, except for azithromycin and ceftriaxone. S. dysenteriae type 1 strains HU8 and BCH518 isolated during 1988 and 1995 from a dysentery outbreak and sporadic infections, respectively, had similar resistance profiles. The two S. dysenteriae type 5 strains were susceptible to ampicillin, fluoroquinolone, azithromycin and ceftriaxone and were resistant to co-trimoxazole, tetracycline, chloramphenicol, nalidixic acid and streptomycin. Except for two strains (NK2685 and NK2683), all the tested S. flexneri strains (n=16) were resistant to co-trimoxazole, tetracycline and streptomycin. Three strains of S. boydii serotype 12 and the majority (94 %) of the S. sonnei strains had an identical resistance pattern (co-trimoxazole, tetracycline, nalidixic acid and streptomycin). The MIC for azithromycin-resistant S. flexneri type 3b (NK2788) and S. boydii type 1 (G24371) was 192 and 128 µg ml–1, respectively. None of the other Shigella strains proved to be resistant to azithromycin and ceftriaxone, in contrast to a recent report from Bangladesh of resistance to these agents among Shigella species (Rahman et al., 2004).
Fluoroquinolone resistance and resistance mechanisms
Ciprofloxacin, norfloxacin and ofloxacin are broad-spectrum fluoroquinolone agents that have excellent activity against most enteric pathogens. Clinical studies have underlined their safe use in adults and children (Bhattacharya et al., 1997; Salam et al., 1998). In this study, 30 % of the Shigella strains were resistant to fluoroquinolones and a S. boydii serotype 1 strain (G24371) was resistant to each of the four compounds tested (Table 2). Due to the unrestricted use of fluoroquinolones in Kolkata for the treatment of diarrhoea and other infectious diseases, resistance to these drugs has been reported among enteric pathogens (Garg et al., 2001; Sinha et al., 2004). In India, this trend has been increasing year on year since 2002 among Shigella species (Pazhani et al., 2005). Fluoroquinolone resistance has also been identified in Shigella isolates in many Asian countries (MoezArdalan et al., 2003; Talukder et al., 2004; von Seidlein et al., 2006) and Canada (CCDR, 2005). At present, fluoroquinolone-resistant S. dysenteriae type 1 and S. flexneri 2a strains remain susceptible to azithromycin and ceftriaxone, which have been reported to be effective against shigellosis in many countries (Khan et al., 1997; Ashkenazi et al., 2003), although cephalosporin resistance has been reported from Spain (Vila et al., 1994) and Argentina (Radice et al., 2001).
S. dysenteriae type 1 strains isolated from sporadic cases of dysentery from Kolkata (BCH518, NK2678 and H16576) and Goa (12567) and outbreak cases from Kolkata, Siliguri, Aizwal and Chandigarh (D2, 21, AZ11 and 115, respectively) were tested for mutations in the gyrA and parC genes. For comparison, we included nalidixic acid-resistant and fluoroquinolone-susceptible S. dysenteriae type 1 strains isolated during 1988 (HU8) and 1995 (BCH518). All fluoroquinolone-resistant strains had a uniform mutation in GyrA at position 83 (replacement of serine with leucine), and the majority of strains had a second mutation at position 87, with replacement of aspartic acid with either glycine or asparagine (Table 2
). However, the S. dysenteriae type 1 strain BCH518, isolated during 1995, had a single mutation in GyrA at position 83, while strain HU8, isolated in Tripura during 1988, had no mutation in gyrA and parC and showed reduced susceptibility to nalidixic acid although it was susceptible to fluoroquinolones (Table 1). However, S. flexneri NK2788, S. boydii G24371 and a S. dysenteriae type 1 strain from the Aizwal outbreak showed amino acid replacement at position 87 (Asp
Asn). To our knowledge, this is the first report of S. boydii having a mutation in gyrA. All the fluoroquinolone-resistant strains had a single mutation in ParC at position 80 (replacement of serine with isoleucine). In a nalidixic acid-resistant S. sonnei strain (NK2017), a mutation was identified at position 83 (replacement of serine with leucine). Fluoroquinolone-resistant strains of S. boydii (G24371), S. flexneri (NK2788) and a representative S. dysenteriae type 1 (12567) strongly exhibited fluoroquinolone efflux (Table 3). The steady state accumulation of norfloxacin and ciprofloxacin was two- to fourfold lower in the resistant strains compared to that in the case of the sensitive strain C152 (Table 3). This suggests that the lower accumulation of fluoroquinolones can also account for the resistance of these strains. After the disruption of the efflux pump with the proton-motive force uncoupler CCCP, the accumulation was almost at the same level in all the tested strains. This clearly suggests that efflux pumps are one of the factors responsible for the development of resistance.
S. dysenteriae type 1 strains from South Asia and Canada had uniform mutations in gyrA and parC (Talukder et al., 2004; CCDR, 2005). A S. dysenteriae strain (BCH518) which was susceptible to fluoroquinolones but resistant to nalidixic acid had an identical mutation in gyrA, similar to that of a 1995 strain isolated in Kolkata (Ahamed et al., 1999). Similarly, mutations in gyrA of S. flexneri and S. sonnei were identical to those reported from other studies (Jeong et al., 2003; Navia et al., 2005). In shigellae, nalidixic acid resistance is not only due to mutations in the QRDR region, but also to an active efflux system (Ahamed et al., 1999). Novel mechanisms for quinolone and fluoroquinolone resistance in members of the Enterobacteriaceae are emerging all the time (Perichon et al., 2007; Yamane et al., 2007), but high-level fluoroquinolone resistance in S. dysenteriae due to a proton-motive force-dependent efflux system was reported almost a decade ago in strains from Kolkata which were devoid of any gyrA mutations (Ghosh et al., 1998).
Plasmid-mediated quinolone resistance due to DNA gyrase protection by a protein from the pentapeptide repeat family called Qnr has recently been described in many clinical isolates of several species (Martinez-Martinez et al., 2003; Jonas et al., 2005). Indeed, clinical strains of S. flexneri type 2b from Japan were found to carry a transferable plasmid, which had 56 % amino acid identity with Qnr (Hata et al., 2005). Based on the amino acid sequence, three subtypes of qnr, i.e. qnrA, qnrB and qnrS, and six variants each in qnrA and qnrB and two in qnrS have also been reported (Nordmann & Poirel, 2005; Cattoir et al., 2007). In this study, none of the strains harboured qnr or its alleles. A novel ciprofloxacin-modifying enzyme (aminoglycoside acetyltransferase) encoding gene aac(6')-Ib-cr was found in members of the Enterobacteriaceae resistant to fluoroquinolones (Park et al., 2006). We have identified the aac(6')-Ib-cr gene in S. boydii type 1 (G24371) and S. flexneri 3b (NK 2788) strains; to our knowledge, this gene has not been reported previously in these Shigella species.
Resistance to other antimicrobials and resistance genes
All the S. dysenteriae type 1 strains harboured blaOXA-1, catA1, tet(B) and strA genes, encoding resistance to ampicillin, chloramphenicol, tetracycline and streptomycin, respectively (Table 1). tet(B) was more common (90 %) than tet(A) (10 %) in S. dysenteriae. Irrespective of serotypes, S. flexneri strains harboured tet(B) as well as blaOXA-1, and in strain NK2788, blaOXA-1, blaTEM-1 and tet(A) genes were detected (Table 1). Group 9 CTX-M β-lactamase has been reported in S. boydii (Vasilev et al., 2007). In this study, blaCTX-M-3 was found in a S. boydii type 1 strain (G24371) and, to our knowledge, this is the first report of this enzyme in this serotype. The majority of S. sonnei strains harboured strA (88 %) and tet(A) (76 %) genes rather than aadA1 and tet(B) (6 % each). Genes encoding resistance to kanamycin (aph1a), gentamicin (aadB) and tetracycline [tet(C), tet(D), tet(E) and tet(Y)] were not found (data not shown). The chromosomal multi-antibiotic resistance locus of S. flexneri type 2a (Rajakumar et al., 1997) was identified, supporting its common occurrence among several serotypes of S. flexneri (Casalino et al., 1994; Thong et al., 2002). We found 97 % and 3 % of ampicillin-resistant Shigella strains harbouring blaOXA-1 and blaTEM-1 genes, respectively. The predominance of blaOXA-1 in Shigella has been reported from many countries (Maraki et al., 1998; Siu et al., 2000; Huang et al., 2005). Similar to the reports from Mexico and Brazil (Martinez-Salazar et al., 1986; Peirano et al., 2005), we found a high frequency of tet(B) among S. flexneri strains, and in common with some South American Shigella strains (Peirano et al., 2005), the presence of the chloramphenicol-resistance gene catA1, which encodes chloramphenicol O-acetyltransferase, and streptomycin resistance was confirmed in S. flexneri strains with either strA or aadA1 genes or both (Table 1).
PFGE analysis
It was necessary to determine whether the frequency of antimicrobial resistance and its determinants was due to the widespread occurrence of specific clones. Two S. dysenteriae type 5 strains (NK2440 and NK2454) had identical XbaI restriction patterns by PFGE, but were different from serotype 1 strains, which had similar patterns (Fig. 1), which are akin to the previously reported PFGE profile (Pazhani et al., 2004). Sixteen strains representing different serotypes of S. flexneri showed extensive variation in PFGE profile (Fig. 2) but six strains of type 2a were identical and clustered closest to two strains of serotype 2b. The remainder of the S. flexneri serotypes were distinct in DNA profile. Of the seven S. boydii strains, three belonging to serotype 12 were closely related in DNA profile while the remainder were distinct (Fig. 3). Eleven of the 17 S. sonnei strains were identical in DNA pattern and two strains clustered closely to this group, being different by two to three bands (Fig. 4). This underlines the findings by others of the clonal nature of S. sonnei (Alcoba-Florez et al., 2005; Mammina et al., 2005).
Although PFGE has proved to be a powerful tool for the discrimination of strains and identification of clonal lineages in several bacterial species, in some S. boydii serotypes it may not be as indicative of absolute strain relatedness. Woodward et al. (2005) reported that strains of S. boydii serotypes 1, 18, 19 and 20 from Canada gave highly similar XbaI macrorestriction patterns, which suggests that some strains that express different lipopolysaccharide antigen epitopes share a common genetic background. Other serotypes were genetically heterogeneous. The population structure of this species therefore warrants further investigation with complementary molecular tools such as multilocus sequence typing.
In conclusion, we have identified multidrug resistance among several serotypes of Shigella species isolated from acute diarrhoeal patients. Irrespective of the serogroup/serotype, most of the strains carried similar genes encoding resistance to specific antimicrobials. It is evident that fluoroquinolone resistance is spreading across different serogroups of Shigella species as they all carried mutations in the gyrA gene. With few exceptions, multidrug-resistant Shigella strains belonged to distinct clones.
|
ACKNOWLEDGEMENTS
|
|---|
This study was supported in part by the Ministry of Education, Culture, Sports, Science and Technology (grant 17406012), Ministry of Health, Labor and Family Welfare of Japan (Project H17- Shinkou-3) and the Japan International Co-operation Agency (JICA/NICED Project 054-1061-E-0) Tokyo, Japan.
|
REFERENCES
|
|---|
Ahamed, J., Gangopadhyay, J., Kundu, M. & Sinha, A. K. (1999). Mechanisms of quinolone resistance in clinical isolates of Shigella dysenteriae. Antimicrob Agents Chemother 43, 2333–2334.[Free Full Text]
Alcoba-Florez, J., Perez-Roth, E., Gonzalez-Linares, S. & Mendez-Alvarez, S. (2005). Outbreak of Shigella sonnei in a rural hotel in La Gomera, Canary Islands, Spain. Int Microbiol 8, 133–136.[Medline]
Ashkenazi, S., Levy, I., Kazaronovski, V. & Samra, Z. (2003). Growing antimicrobial resistance of Shigella isolates. J Antimicrob Chemother 51, 427–429.[Abstract/Free Full Text]
Bhattacharya, S. K., Bhattacharya, M. K., Dutta, D., Dutta, S., Deb, M., Deb, A., Das, K. P., Kole, H. & Nair, G. B. (1997). Double-blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children. Acta Paediatr 86, 319–320.[CrossRef][Medline]
Casalino, M., Nicoletti, M., Salvia, A., Colonna, B., Pazzani, C., Calconi, A., Mohamud, K. A. & Maimone, F. (1994). Characterization of endemic Shigella flexneri strains in Somalia: antimicrobial resistance, plasmid profiles, and serotype correlation. J Clin Microbiol 32, 1179–1183.[Abstract/Free Full Text]
Cattoir, V., Poirel, L., Rotimi, V., Soussy, C.-J. & Nordmann, P. (2007). Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. J Antimicrob Chemother 60, 394–397.[Abstract/Free Full Text]
CCDR (2005). Emergence of quinolone-resistant Shigella dysenteriae type 1 in Canada. Can Commun Dis Rep 31, 193–197.[Medline]
CDC (2000). PulseNet PFGE Manual. Atlanta: Centers for Disease Control and Prevention.
Chu, Y. W., Houang, E. T. S. & Cheng, A. F. B. (1998). Novel combination of mutations in the DNA gyrase and topoisomerase IV genes in laboratory-grown fluoroquinolone-resistant Shigella flexneri mutants. Antimicrob Agents Chemother 42, 3051–3052.[Free Full Text]
Garg, P., Shina, S., Chakraborty, R., Bhattacharya, S. K., Nair, G. B., Ramamurthy, T. & Takeda, Y. (2001). Emergence of fluoroquinolone-resistant strains of Vibrio cholerae O1 biotype El Tor among hospitalized patients with cholera in Kolkata, India. Antimicrob Agents Chemother 45, 1605–1606.[Free Full Text]
Ghosh, A. S., Ahamed, J., Chauhan, K. K. & Kundu, M. (1998). Involvement of an efflux system in high-level fluoroquinolone resistance of Shigella dysenteriae. Biochem Biophys Res Commun 242, 54–56.[CrossRef][Medline]
Hata, M., Suzuki, M., Matsumoto, M., Takahashi, M., Sato, K., Ibe, S. & Sakae, K. (2005). Cloning of a novel gene for quinolone resistance from a transferable plasmid in Shigella flexneri 2b. Antimicrob Agents Chemother 49, 801–803.[Abstract/Free Full Text]
Huang, I. F., Chiu, C. H., Wang, M. H., Wu, C. Y., Hsieh, K. S. & Chiou, C. (2005). Outbreak of dysentery associated with ceftriaxone-resistant Shigella sonnei: first report of plasmid-mediated CMY-2-type AmpC beta-lactamase resistance in S. sonnei. J Clin Microbiol 43, 2608–2612.[Abstract/Free Full Text]
Jeong, Y. S., Lee, J. C., Kang, H. Y., Yu, H. S., Lee, E. Y., Choi, C. H., Tae, S. H., Lee, Y. C., Cho, D. T. & Seol, S. Y. (2003). Epidemiology of nalidixic acid resistance and TEM-1- and TEM-52-mediated ampicillin resistance of Shigella sonnei isolates obtained in Korea between 1980 and 2000. Antimicrob Agents Chemother 47, 3719–3723.[Abstract/Free Full Text]
Jonas, D., Biehler, K., Hartung, D., Spitzmuller, B. & Daschner, F. D. (2005). Plasmid-mediated quinolone resistance in isolates obtained in German intensive care units. Antimicrob Agents Chemother 49, 773–775.[Abstract/Free Full Text]
Kariuki, S. & Hart, C. A. (2001). Global aspects of antimicrobial-resistant enteric bacteria. Curr Opin Infect Dis 14, 579–586.[Medline]
Khan, W. A., Seas, C., Dhar, U., Salam, M. A. & Bennish, M. L. (1997). Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann Intern Med 126, 697–703.[Abstract/Free Full Text]
Maidhof, H., Guerra, B., Abbas, S., Elsheikha, H., Whittam, T. S. & Beutin, L. (2002). A multiresistant clone of Shiga toxin-producing E. coli O118:[H16] is spread in cattle and humans over different European countries. Appl Environ Microbiol 68, 5834–5842.[Abstract/Free Full Text]
Mammina, C., Pontello, M., Dal Vecchio, A. & Nastasi, A., & the , S. sonnei Working Group (2005). Identification of Shigella sonnei biotype g isolates carrying class 2 integrons in Italy (2001 to 2003). J Clin Microbiol 43, 2467–2470.[Abstract/Free Full Text]
Maraki, S., Georgiladakis, A., Christidou, A., Scoulica, E. & Tselentis, Y. (1998). Antimicrobial susceptibilities and beta-lactamase production of Shigella isolates in Crete, Greece, during the period 1991–1995. APMIS 106, 879–883.[Medline]
Martinez-Martinez, L., Pascual, A., Garcia, I., Tran, J. & Jacoby, G. A. (2003). Interaction of plasmid and host quinolone resistance. J Antimicrob Chemother 51, 1037–1039.[Free Full Text]
Martinez-Salazar, J. M., Alvarez, G. & Gomez-Eichlmann, M. C. (1986). Frequency of four classes of tetracycline resistance determinants in Salmonella and Shigella spp. clinical isolates. Antimicrob Agents Chemother 30, 630–631.[Abstract/Free Full Text]
Maynard, C., Fairbrother, J. M., Bekal, S., Sanschagrin, F., Levesque, R. C., Brousseau, R., Masson, L., Lariviere, S. & Harel, J. (2003). Antimicrobial resistance genes in enterotoxigenic Escherichia coli O149:K91 isolates obtained over a 23-year period from pigs. Antimicrob Agents Chemother 47, 3214–3221.[Abstract/Free Full Text]
MoezArdalan, K., Zali, M. R., Dallal, M. M., Hemami, M. R. & Salmanzadeh-Ahrabi, S. (2003). Prevalence and pattern of antimicrobial resistance of Shigella species among patients with acute diarrhoea in Karaj, Tehran, Iran. J Health Popul Nutr 21, 96–102.[Medline]
Navia, M. M., Gascon, J. & Vila, J. (2005). Analysis of the mechanisms of resistance to several antimicrobial agents in Shigella spp. causing travellers' diarrhoea. Clin Microbiol Infect 11, 1044–1047.[CrossRef][Medline]
NCCLS (2004). Performance Standards for Antimicrobial Susceptibility Testing. Approved Standards, 14th edn. Document M100-S14. Villanova, PA: National Committee for Clinical Laboratory Standards.
Nordmann, P. & Poirel, L. (2005). Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. J Antimicrob Chemother 56, 463–469.[Abstract/Free Full Text]
Park, C. H., Robicsek, A., Jacby, G. A., Sahm, D. & Hooper, D. C. (2006). Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin modifying enzyme. Antimicrob Agents Chemother 50, 3953–3955.[Abstract/Free Full Text]
Pazhani, G. P., Sarkar, B., Ramamurthy, T., Bhattacharya, S. K., Takeda, Y. & Niyogi, S. K. (2004). Clonal multidrug-resistant Shigella dysenteriae type 1 strains associated with epidemic and sporadic dysenteries in eastern India. Antimicrob Agents Chemother 48, 681–684.[Abstract/Free Full Text]
Pazhani, G. P., Ramamurthy, T., Mitra, U., Bhattacharya, S. K. & Niyogi, S. K. (2005). Species diversity and antimicrobial resistance of Shigella spp. isolated between 2001 and 2004 from hospitalized children with diarrhoea in Kolkata (Calcutta), India. Epidemiol Infect 133, 1089–1095.[CrossRef][Medline]
Peirano, G., Agerso, Y., Aarestrup, F. M. & dos Prazeres Rodrigues, D. (2005). Occurrence of integrons and resistance genes among sulphonamide-resistant Shigella spp. from Brazil. J Antimicrob Chemother 55, 301–305.[Abstract/Free Full Text]
Perichon, B., Courvalin, P. & Galimand, M. (2007). Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. Antimicrob Agents Chemother 51, 2464–2469.[Abstract/Free Full Text]
Radice, M., Gonzealez, C., Power, P., Vidal, M. C. & Gutkind, G. (2001). Third-generation cephalosporin resistance in Shigella sonnei, Argentina. Emerg Infect Dis 7, 442–443.[Medline]
Rahman, M., Shoma, S., Rashid, H., Siddique, A. K., Nair, G. B. & Sack, D. A. (2004). Extended-spectrum beta-lactamase-mediated third-generation cephalosporin resistance in Shigella isolates in Bangladesh. J Antimicrob Chemother 54, 846–847.[Free Full Text]
Rajakumar, K., Bulach, D., Davies, J., Ambrose, L., Sasakawa, C. & Adler, B. (1997). Identification of a chromosomal Shigella flexneri multi-antibiotic resistance locus, which shares sequence and organizational similarity with the resistance region of the plasmid NR1. Plasmid 37, 159–168.[CrossRef][Medline]
Robicsek, A., Strahilevitz, J., Sahm, D. F., Jacoby, G. A. & Hooper, D. C. (2006). qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob Agents Chemother 50, 2872–2874.[Abstract/Free Full Text]
Salam, M. A. & Bennish, M. L. (1991). Antimicrobial therapy for shigellosis. Rev Infect Dis 13 (Suppl. 4), S332–S341.[Medline]
Salam, M. A., Dhar, U., Khan, W. A. & Bennsih, M. L. (1998). Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet 352, 522–527.[CrossRef][Medline]
Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989). Molecular Cloning: a Laboratory Manual, 2nd edn, 9.42–45. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
Sinha, S., Chattopadhya, S., Bhattacharya, S. K., Nair, G. B. & Ramamurthy, T. (2004). An unusually high level of quinolone resistance associated with type II topoisomerase mutations in quinolone resistance-determining regions of Aeromonas caviae isolated from diarrhoeal patients. Res Microbiol 155, 827–829.[Medline]
Siu, L. K., Lo, J. Y., Yuen, K. Y., Chau, P. Y., Ng, M. H. & Ho, P. L. (2000). Beta-lactamases in S. flexneri isolates from Hong Kong and Shanghai and a novel OXA-1-like beta-lactamase, OXA-30. Antimicrob Agents Chemother 44, 2034–2038.[Abstract/Free Full Text]
Talukder, K. A., Khajanchi, B. K., Islam, M. A., Dutta, D. K., Islam, Z., Safa, A., Khan, G. Y., Alam, K., Hossain, M. A. & other authors (2004). Genetic relatedness of ciprofloxacin-resistant Shigella dysenteriae type 1 strains isolated in south Asia. J Antimicrob Chemother 54, 730–734.[Abstract/Free Full Text]
Thong, K. L., Hoe, C. H., Koh, Y. T. & Yasin, R. M. (2002). Prevalence of multidrug-resistant Shigella isolated in Malaysia. J Health Popul Nutr 20, 356–358.[Medline]
Vasilev, V., Japheth, R., Yishai, R., Andorn, N., Valinsky, L., Navon-Venezia, S., Chmelnitsky, I., Carmeli, Y. & Chohen, D. (2007). Extended-spectrum beta-lactamase-producing Shigella strains in Israel, 2000–2004. Eur J Clin Microbiol Infect Dis 26, 189–194.[CrossRef][Medline]
Vila, J., Gascon, J., Abdalla, S., Gomez, J., Marco, F., Moreno, A., Corachan, M. & Jimenez de Anta, T. (1994). Antimicrobial resistance of Shigella isolates causing traveler's diarrhoea. Antimicrob Agents Chemother 38, 2668–2670.[Abstract/Free Full Text]
von Seidlein, L., Kim, D. R., Ali, M., Lee, H., Wang, X., Thiem, V. D., Canh, D. G., Chaicumpa, W., Agtini, M. D. & other authors (2006). A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med 3, e353[CrossRef][Medline]
Wang, M., Tran, J. H., Jacoby, G. A., Zhang, Y., Wang, F. & Hooper, C. (2003). Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrob Agents Chemother 47, 2242–2248.[Abstract/Free Full Text]
WHO (1987). Manual for Laboratory Investigation of Acute Enteric Infections. CDD/83.3. Geneva, Switzerland: World Health Organization.
WHO (2004). International note on antibiotics in the management of shigellsosis. Wkly Epidemiol Rec 79, 202–203.
Woodward, D. L., Clark, C. G., Caldeira, R. A., Ahmed, R., Soule, G., Bryden, L., Tabor, H., Melito, P., Foster, R. & other authors (2005). Identification and characterization of Shigella boydii 20 serovar nov., a new and emerging Shigella serotype. J Med Microbiol 54, 741–748.[Abstract/Free Full Text]
Yamane, K., Wachinoo, J. I., Suzuki, S., Kimura, K., Shibata, N., Kato, H., Shibayama, K., Konda, T. & Arakawa, Y. (2007). New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrob Agents Chemother 51, 3354–3360.[Abstract/Free Full Text]
This article has been cited by other articles:
|
|
|
|
 
X.-Y. Pu, J.-C. Pan, H.-Q. Wang, W. Zhang, Z.-C. Huang, and Y.-M. Gu
Characterization of fluoroquinolone-resistant Shigella flexneri in Hangzhou area of China
J. Antimicrob. Chemother.,
May 1, 2009;
63(5):
917 - 920.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Vrints, E. Mairiaux, E. Van Meervenne, J.-M. Collard, and S. Bertrand
Surveillance of Antibiotic Susceptibility Patterns among Shigella sonnei Strains Isolated in Belgium during the 18-Year Period 1990 to 2007
J. Clin. Microbiol.,
May 1, 2009;
47(5):
1379 - 1385.
[Abstract]
[Full Text]
[PDF]
|
|
|
TOP
INTRODUCTION
METHODS
